Australien - Englisch - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - cefazolin sodium, quantity: 2096 mg - injection, powder for - excipient ingredients: - cefazolin is indicated in the treatment of the following serious infections due to susceptible organisms:,respiratory tract infections due to s. pneumoniae, klebsiella species, h. influenzae, staph. aureus (penicillin-sensitive and penicillin- resistant), and group a beta-haemolytic streptococci.,injectable benzathine penicillin is considered to be the drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever.,cefazolin is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of cefazolin in the subsequent prevention of rheumatic fever are not available at present.,genitourinary tract infections due to esch. coli, pr. mirabilis, klebsiella species, and some strains of enterobacter and enterococci.,skin and skin structure infections due to staph. aureus (penicillin-sensitive and penicillin- resistant), and group a beta-haemolytic streptococci and other strains of streptococci.,bone and joint infections due to staph. aureus.,septicaemia due to s. pneumoniae, staph. aureus (penicillin-sensitive and penicillin-resistant), pr. mirabilis, esch. coli and klebsiella species.,endocarditis due to staph. aureus (penicillin-sensitive and penicillin-resistant), and group a beta-haemolytic streptococci.,appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefazolin.

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - cefazolin sodium, quantity: 2096 mg - injection, powder for - excipient ingredients: - cefazolin is indicated in the treatment of the following serious infections due to susceptible organisms:,respiratory tract infections due to s. pneumoniae, klebsiella species, h. influenzae, staph. aureus (penicillin-sensitive and penicillin- resistant), and group a beta-haemolytic streptococci.,injectable benzathine penicillin is considered to be the drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever.,cefazolin is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of cefazolin in the subsequent prevention of rheumatic fever are not available at present.,genitourinary tract infections due to esch. coli, pr. mirabilis, klebsiella species, and some strains of enterobacter and enterococci.,skin and skin structure infections due to staph. aureus (penicillin-sensitive and penicillin- resistant), and group a beta-haemolytic streptococci and other strains of streptococci.,bone and joint infections due to staph. aureus.,septicaemia due to s. pneumoniae, staph. aureus (penicillin-sensitive and penicillin-resistant), pr. mirabilis, esch. coli and klebsiella species.,endocarditis due to staph. aureus (penicillin-sensitive and penicillin-resistant), and group a beta-haemolytic streptococci.,appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefazolin.

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - cefazolin sodium, quantity: 1048 mg - injection, powder for - excipient ingredients: - cefazolin is indicated in the treatment of the following serious infections due to susceptible organisms:,respiratory tract infections due to s. pneumoniae, klebsiella species, h. influenzae, staph. aureus (penicillin-sensitive and penicillin- resistant), and group a beta-haemolytic streptococci.,injectable benzathine penicillin is considered to be the drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever.,cefazolin is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of cefazolin in the subsequent prevention of rheumatic fever are not available at present.,genitourinary tract infections due to esch. coli, pr. mirabilis, klebsiella species, and some strains of enterobacter and enterococci.,skin and skin structure infections due to staph. aureus (penicillin-sensitive and penicillin- resistant), and group a beta-haemolytic streptococci and other strains of streptococci.,bone and joint infections due to staph. aureus.,septicaemia due to s. pneumoniae, staph. aureus (penicillin-sensitive and penicillin-resistant), pr. mirabilis, esch. coli and klebsiella species.,endocarditis due to staph. aureus (penicillin-sensitive and penicillin-resistant), and group a beta-haemolytic streptococci.,appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefazolin.

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - cefazolin sodium, quantity: 524 mg - injection, powder for - excipient ingredients: - cefazolin is indicated in the treatment of the following serious infections due to susceptible organisms:,respiratory tract infections due to s. pneumoniae, klebsiella species, h. influenzae, staph. aureus (penicillin-sensitive and penicillin- resistant), and group a beta-haemolytic streptococci.,injectable benzathine penicillin is considered to be the drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever.,cefazolin is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of cefazolin in the subsequent prevention of rheumatic fever are not available at present.,genitourinary tract infections due to esch. coli, pr. mirabilis, klebsiella species, and some strains of enterobacter and enterococci.,skin and skin structure infections due to staph. aureus (penicillin-sensitive and penicillin- resistant), and group a beta-haemolytic streptococci and other strains of streptococci.,bone and joint infections due to staph. aureus.,septicaemia due to s. pneumoniae, staph. aureus (penicillin-sensitive and penicillin-resistant), pr. mirabilis, esch. coli and klebsiella species.,endocarditis due to staph. aureus (penicillin-sensitive and penicillin-resistant), and group a beta-haemolytic streptococci.,appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefazolin.

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - cefazolin sodium, quantity: 1048 mg - injection, powder for - excipient ingredients: - cefazolin is indicated in the treatment of the following serious infections due to susceptible organisms:,respiratory tract infections due to s. pneumoniae, klebsiella species, h. influenzae, staph. aureus (penicillin-sensitive and penicillin- resistant), and group a beta-haemolytic streptococci.,injectable benzathine penicillin is considered to be the drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever.,cefazolin is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of cefazolin in the subsequent prevention of rheumatic fever are not available at present.,genitourinary tract infections due to esch. coli, pr. mirabilis, klebsiella species, and some strains of enterobacter and enterococci.,skin and skin structure infections due to staph. aureus (penicillin-sensitive and penicillin- resistant), and group a beta-haemolytic streptococci and other strains of streptococci.,bone and joint infections due to staph. aureus.,septicaemia due to s. pneumoniae, staph. aureus (penicillin-sensitive and penicillin-resistant), pr. mirabilis, esch. coli and klebsiella species.,endocarditis due to staph. aureus (penicillin-sensitive and penicillin-resistant), and group a beta-haemolytic streptococci.,appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefazolin.

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - cefazolin sodium, quantity: 524 mg - injection, powder for - excipient ingredients: - cefazolin is indicated in the treatment of the following serious infections due to susceptible organisms:,respiratory tract infections due to s. pneumoniae, klebsiella species, h. influenzae, staph. aureus (penicillin-sensitive and penicillin- resistant), and group a beta-haemolytic streptococci.,injectable benzathine penicillin is considered to be the drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever.,cefazolin is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of cefazolin in the subsequent prevention of rheumatic fever are not available at present.,genitourinary tract infections due to esch. coli, pr. mirabilis, klebsiella species, and some strains of enterobacter and enterococci.,skin and skin structure infections due to staph. aureus (penicillin-sensitive and penicillin- resistant), and group a beta-haemolytic streptococci and other strains of streptococci.,bone and joint infections due to staph. aureus.,septicaemia due to s. pneumoniae, staph. aureus (penicillin-sensitive and penicillin-resistant), pr. mirabilis, esch. coli and klebsiella species.,endocarditis due to staph. aureus (penicillin-sensitive and penicillin-resistant), and group a beta-haemolytic streptococci.,appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefazolin.

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - amoxicillin trihydrate, quantity: 574 mg (equivalent: amoxicillin, qty 500 mg) - capsule, hard - excipient ingredients: magnesium stearate; titanium dioxide; gelatin; purified talc - indications as at 6 november 2003: cilamox is indicated for the treatment of infections due to susceptible strains of the sensitive organisms. gram-negative: h. influenzae, e coli, pr. mirabilis, and n. gonorrhoeae. gram-positive: streptococcus species, s. pneumoniae, non-penicllinase producing staphlococci and bacillus anthracis. note 1: cilamox may be useful in instituting therapy prior to bacteriology; however, bacteriological studies to determine the causative organisms and their sensitivity to cilamox should be performed. note 2: penicillins are now generally regarded only as adjunctive to some other established first-line antibiotic therapy in the treatment and post-exposure prophylaxis of anthrax, because of concerns of constitutive and inducible beta-lactamase in bacillus anthracis. if use of amoxycillin is contemplated, appropriate bacteriological studies must be performed by a reliable and established test method. amoxycillin may then be suitable if the specific b. anthracis strain has been shown definitively to be sensitive to penicillin/amaxycillin.

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - amoxicillin trihydrate, quantity: 287 mg (equivalent: amoxicillin, qty 250 mg) - capsule, hard - excipient ingredients: magnesium stearate; gelatin; titanium dioxide; purified talc - indications as at 6 november 2003: cilamox is indicated for the treatment of infections due to susceptible strains of the sensitive organisms. gram-negative: h. influenzae, e coli, pr. mirabilis, and n. gonorrhoeae. gram-positive: streptococcus species, s. pneumoniae, non-penicllinase producing staphlococci and bacillus anthracis. note 1: cilamox may be useful in instituting therapy prior to bacteriology; however, bacteriological studies to determine the causative organisms and their sensitivity to cilamox should be performed. note 2: penicillins are now generally regarded only as adjunctive to some other established first-line antibiotic therapy in the treatment and post-exposure prophylaxis of anthrax, because of concerns of constitutive and inducible beta-lactamase in bacillus anthracis. if use of amoxycillin is contemplated, appropriate bacteriological studies must be performed by a reliable and established test method. amoxycillin may then be suitable if the specific b. anthracis strain has been shown definitively to be sensitive to penicillin/amaxycillin.

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - amoxicillin trihydrate, quantity: 573.9 mg (equivalent: amoxicillin, qty 500 mg) - capsule, hard - excipient ingredients: iron oxide yellow; erythrosine; titanium dioxide; indigo carmine; magnesium stearate; gelatin; purified talc; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; shellac; ethanol absolute; ammonia; potassium hydroxide - indications as at 14th february 2005: it is indicated for the treatment of the following infections due to susceptible strains of sensitive organisms: note; therapy should be guided by bacteriological studies, including sensitivity tests, and by clinical response. however, in emergency cases where the causative organism has not been identified, therapy with amoxycillin may be useful. clinical judgement will decide whether combination with another antibiotic would provide a sufficiently broad spectrum of activity pending sensitivity test results. skin and skin structure: staphylococcus, non-penicillinase producing; streptococcus; e.coli (see microbiology). respiratory (acute and chronic): h.influenzae, streptococcus; s.pneumoniae; staphylococcus, non-penicillinase-producing; e.coli (see microbiology). genitourinary tract (complicated and uncomplicated, acute and chronic): e.coli (see microbiology), p.mirabilis and s.faecalis. gonorrhoea: n.gonorrhoeae (non-penicillinase producing). prophylaxis of endocarditis: amoxil may be used for the prophylaxis of bacterial endocarditis in individuals at particular risk, such as those with a prosthetic heart valve or those who have previously had endocarditis.

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - amoxicillin trihydrate, quantity: 286.95 mg (equivalent: amoxicillin, qty 250 mg) - capsule, hard - excipient ingredients: erythrosine; iron oxide yellow; titanium dioxide; magnesium stearate; gelatin; indigo carmine; purified talc; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; shellac; ethanol absolute; ammonia; potassium hydroxide - indications as at 14th february 2005: it is indicated for the treatment of the following infections due to susceptible strains of sensitive organisms: note; therapy should be guided by bacteriological studies, including sensitivity tests, and by clinical response. however, in emergency cases where the causative organism has not been identified, therapy with amoxycillin may be useful. clinical judgement will decide whether combination with another antibiotic would provide a sufficiently broad spectrum of activity pending sensitivity test results. skin and skin structure: staphylococcus, non-penicillinase producing; streptococcus; e.coli (see microbiology). respiratory (acute and chronic): h.influenzae, streptococcus; s.pneumoniae; staphylococcus, non-penicillinase-producing; e.coli (see microbiology). genitourinary tract (complicated and uncomplicated, acute and chronic): e.coli (see microbiology), p.mirabilis and s.faecalis. gonorrhoea: n.gonorrhoeae (non-penicillinase producing). prophylaxis of endocarditis: amoxil may be used for the prophylaxis of bacterial endocarditis in individuals at particular risk, such as those with a prosthetic heart valve or those who have previously had endocarditis.